Jivi under the microscope: new study tracks safety in korean hemophilia patients

NCT ID NCT06222697

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitors the safety of Jivi (damoctocog alfa pegol) in 20 Korean patients with hemophilia A who have used other treatments before. Researchers will collect data from routine clinic visits over about 8 months per participant, looking for any medical problems. No extra tests or visits are required, as this is an observational study of real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: damoctocog alfa pegol (Jivi)
What this could lead to: If this study succeeds, it could confirm that Jivi is safe and effective for Korean patients with hemophilia A in real-world settings.
What could go wrong: This is a small, observational study with only 20 participants, so results may not apply to everyone. It does not test new uses or compare Jivi to other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A PROPHYLAXIS OF BLEEDING TREATMENT OF BLEEDING

Contacts and locations

Locations

Many Locations
RECRUITING

Multiple Locations, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.